A comprehensive multicenter study assessing the impact of abelacimab, asundexian, and milvexian on coagulation assays.

Goubeau L, Curis E, Delavenne X, Gouin-Thibault I, Hodin S, Genin A, Demagny J, Menard F, Faille D, Mouton C, De Maistre E, Fontana P, Mauge L, Dupont A, Nougier C, Hézard N, Boissier E, Lasne D, Grand F, Billoir P, Herb A, Frere C, Voisin S, Sillamy N, Flaujac C, Mullier F, Siguret V, Jourdi G

Open source

DOI: 10.1182/bloodadvances.2026020472
Published: 2026 Sep 8
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2026020472,
  title = {A comprehensive multicenter study assessing the impact of abelacimab, asundexian, and milvexian on coagulation assays.},
  author = {Goubeau L and Curis E and Delavenne X and Gouin-Thibault I and Hodin S and Genin A and Demagny J and Menard F and Faille D and Mouton C and De Maistre E and Fontana P and Mauge L and Dupont A and Nougier C and Hézard N and Boissier E and Lasne D and Grand F and Billoir P and Herb A and Frere C and Voisin S and Sillamy N and Flaujac C and Mullier F and Siguret V and Jourdi G},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2026020472},
  url = {https://doi.org/10.1182/bloodadvances.2026020472}
}

RIS

TY  - JOUR
TI  - A comprehensive multicenter study assessing the impact of abelacimab, asundexian, and milvexian on coagulation assays.
AU  - Goubeau L
AU  - Curis E
AU  - Delavenne X
AU  - Gouin-Thibault I
AU  - Hodin S
AU  - Genin A
AU  - Demagny J
AU  - Menard F
AU  - Faille D
AU  - Mouton C
AU  - De Maistre E
AU  - Fontana P
AU  - Mauge L
AU  - Dupont A
AU  - Nougier C
AU  - Hézard N
AU  - Boissier E
AU  - Lasne D
AU  - Grand F
AU  - Billoir P
AU  - Herb A
AU  - Frere C
AU  - Voisin S
AU  - Sillamy N
AU  - Flaujac C
AU  - Mullier F
AU  - Siguret V
AU  - Jourdi G
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2026020472
UR  - https://doi.org/10.1182/bloodadvances.2026020472
ER  -

APA

L, G., E, C., X, D., I, G., S, H., A, G., J, D., F, M., D, F., C, M., E, D. M., P, F., L, M., A, D., C, N., N, H., E, B., D, L., F, G., P, B., A, H., C, F., S, V., N, S., C, F., F, M., V, S., & G, J. (2026). A comprehensive multicenter study assessing the impact of abelacimab, asundexian, and milvexian on coagulation assays.. Blood advances. https://doi.org/10.1182/bloodadvances.2026020472

Source records

pubmed · retrieved 2026-09-27T16:11:22.094Z